Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Sponsor
Novo Nordisk A/S
Study ID
NCT06351748
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.

Study Details

This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.

Key Dates

Start date
Jan 2, 2024
Status verified
Apr 2025
Primary completion
Mar 29, 2024
Completion
Mar 29, 2024

Study Design

Enrollment
34,238 participants (actual)

Arms

  • Arm: Participants with T2DM
    Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China) and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023.

Primary Outcome Measure

Change in Haemoglobin A1c (HbA1c) level [ Time Frame: From baseline (3 months prior to or on the index date) to 6 months ]

Related Studies